Centocor's Stelara meets study endpoints in Crohn's disease Phase IIb trial
This article was originally published in Scrip
Executive Summary
Centocor Ortho Biotech's (Johnson & Johnson) cytokine antagonist Stelara (ustekinumab) has shown promising efficacy in a Phase IIb study of Crohn's disease patients who had previously had inadequate response to tumour necrosis factor antagonists.